- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06786130
Societal Burden Associated With Type 1 Diabetes in Canada (T1D)
December 22, 2025 updated by: PeriPharm
Burden and (Dis)Utility of Caregivers of Children With T1D
The purpose of this observational study is to estimate the burden of T1D on caregivers of patient with T1D in terms of work productivity, healthcare resource utilization and quality of life.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H2Y 2H4
- Recruiting
- PROxy Network, an initiative of PeriPharm inc.
-
Contact:
- Catherine Beauchemin, PhD
- Phone Number: 102 514-731-8207
- Email: catherine.beauchemin@peripharm.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Parental caregivers of a child with T1D
Description
Inclusion Criteria:
- Parental caregiver of a child recently diagnosed (<= 2 years) with T1D before study inclusion;
- Age ≥18 ;
- Residence in the Canada;
- Willingess to complete a 20-minute survey
- Ability to read and understand French or English;
- Signature of informed consent form (ICF)
Exclusion Criteria:
1. Participation in a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Caregiver of child with T1D
Caregiver of child with T1D diagnosed within the past 2 years
|
This is an observational study in which participants complete PRO questionnaires via a web platform.
No medical intervention or medication is involved.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To estimate work productivity impairment of caregivers of a T1D child.
Time Frame: At recruitment
|
Using the WOrk Productivity and Activity Impairment (WPAI) questionnaire
|
At recruitment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To estimate healthcare resource utilization in caregivers of T1D child
Time Frame: At recruitment
|
Using the modified Resource Utilization Questionnaire for Type 1 Diabetes (mRUQ-T1DM) questionnaire.
|
At recruitment
|
|
To estimate health-related quality of life in caregivers of a T1D child
Time Frame: At recruitment
|
Using the EuroQOL-5 dimension-5 levels (EQ-5D-5L) questionnaire.
|
At recruitment
|
|
To estimate the caregiver burden in caregivers of a T1D child
Time Frame: At recruitment
|
Using the Zarit Burden Interview-22 (ZBI-22) questionnaire.
|
At recruitment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 9, 2025
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
September 16, 2024
First Submitted That Met QC Criteria
January 14, 2025
First Posted (Actual)
January 22, 2025
Study Record Updates
Last Update Posted (Actual)
December 23, 2025
Last Update Submitted That Met QC Criteria
December 22, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BOD0250
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
-
Sultan Qaboos UniversityUniversity of Mosul; University of Child Health Sciences and Children's Hospital...Not yet recruitingType 1 Diabetes Mellitus | T1DM | Type 1 Diabetes Mellitus (T1DM) | T1DM - Type 1 Diabetes Mellitus
-
Lund UniversityEnrolling by invitationType 1 Diabetes Mellitus | Stage 2 Type 1 Diabetes | Stage 1 Type 1 Diabetes | Stage 3 Type 1 DiabetesSweden
-
Superior UniversityActive, not recruitingType 2 Diabetes Mellitus 1Pakistan
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Immunocore LtdNot yet recruitingType 1 Diabetes | Diabetes Type 1 | Type 1 Diabetes (T1D)
-
Abdullah KarsNot yet recruitingType 1 Diabetes Mellitus | Autoimmune Diabetes | Type 1 Diabetes Mellitus (T1DM)Turkey (Türkiye)
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
Clinical Trials on observational study
-
Taysha Gene Therapies, Inc.Withdrawn
-
University of Castilla-La ManchaRecruitingKnee OsteoarthritisSpain
-
University of ManitobaCompletedObesity | Pregnancy | Cesarean SectionCanada
-
Drexel UniversityCompletedOsteoporosisUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Merck Sharp & Dohme LLCRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Roswell Park Cancer InstituteRecruitingCigarette Smoking-Related CarcinomaUnited States
-
Children's Oncology GroupNot yet recruitingChildhood Hematopoietic and Lymphatic System Neoplasm | Childhood Malignant Solid Neoplasm
-
Ohio State University Comprehensive Cancer CenterAmerican Association for Cancer ResearchRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Breast Carcinoma | Hormone Receptor-Positive Breast CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)Not yet recruitingEndometrial CarcinomaUnited States